Correlating telomerase activity levels with human neuroblastoma outcomes

Nature Medicine

Volumn 1, Issue 3, 1995, Pages 249-255

  Hiyama, Eiso ^a,b   Hiyama, Keiko ^a,b   Yokoyama, Takashi ^b   Matsuura, Yuichiro ^b   Piatyszek, Mieczyslaw A ^a   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL GLAND; ARTICLE; CONTROLLED STUDY; GANGLIONEUROMA; GENE MUTATION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TELOMERE;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; BASE SEQUENCE; CHILD; DNA PRIMERS; GANGLIONEUROMA; HUMAN; INFANT; MALE; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TELOMERASE; TELOMERE;

EID: 84993876589     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0395-249     Document Type: Article

References (56)

1. Blackburn, E.H. Telomerases. Amu. Rev. Biochem. 61, 113-129 (1992).
2. Zakian, V.A. Structure and function of telomeres. Annu. Rev Genet. 23, 579-604 (1989).
3. De Lange, T. Activation of telomerase in a human tumour. Proc. natn. Acad. Sci. U.SA. 91, 2882-2885 (1994).
4. Watson, J.D. Origin of concatemeric T7 DNA. Nature New Biolo. (London) 239, 197-201 (1972).
5. Olovnikov, A.M. A theory of marginotomy. J. Theor. Biol. 41, 181-190 (1973).
6. Levy, M.Z., Allsopp, R.C, Futcher, A.B., Greider, C.W. & Harley, C. B. Telomere end-replication problem and cell aging. J. molec. Biol 225, 951-960 (1992).
7. Harley, C.B., Futcher, A.B. & Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990).
8. Allsopp, R.C. et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. natn. Acad. Sci. U.SA. 89, 10114-10118 (1992).
9. Vaziri, H. et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 52, 661-669 (1993).
10. Shay J.W., Wright W.E., Brasiskyte D., & Van Der Haegen B.A. E6 of human papillomavirus type 16 can overcome the Ml stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 8, 1407-1413 (1993).
11. Shay, J.W., Wright, W.E., & Werbin, H. Toward a molecular understanding of human breast cancer: a hypothesis. Breast Cancer. Res. Treat, 25, 83-94 (1993).
12. Kim, N.-W. et al. Specific association of human telomerase activity with immortal cells and cancer. Sdence, 266, 2011-2015 (1994).
13. Mantell, L.L. & Greider, C.W. Telomerase activity in germline and embryonic cells otXenopus. EMBOJ. 13, 3211-3217 (1994).
14. Counter, C.M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921-1929 (1992).
15. Morin, G.B. The human telomere terminal transferase enzyme is a ribonucleo- protein that synthesizes TTAGGG repeats. Cell 59, 521-529 (1989).
16. Greider, C.W. Telomeres, telomerase and senescence. Bioessays 12, 363-369 (1990).
17. Greider, C.W. & Blackbum, E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405-413 (1985).
18. Allshire, R.C., Dempster, M. & Hastie, N.D. Human telomeres contain at least three types of G-rich repeat distributed non-randomly. Nucl Acids Res. 17, 4611-4627 (1989).
19. Hastie, N.D. et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866-868 (1990).
20. Lindsey, J., McGill, N.I., Lindsey, L.A., Green, D.K., & Cooke, H.J. In vivo loss of telomeric repeats with age in humans Mutat. Res. 256, 45-48 (1991).
21. Harley, C.B., Telomere loss: Mitotic clock or genetic time bomb. Mutat Res. 256, 271-282 (1991).
22. Wright, W.E. & Shay, J.W. Telomere positional effects and the regulation of cellular senescence. Trends Genet. 8, 193-198 (1992).
23. Shay, J.W., Wright, W.E. & Werbin, H. Loss of telomeric DNA during aging may predispose cells to cancer (Review). Int. J. Oncol 3, 559-563 (1993).
24. Wright, W.E. & Shay, J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp. Geront. 27, 383-389 (1992).
25. Shay, J.W., Werbin, H. & Wright, W.E. Telomere shortening may contribute to aging and cancer: A perspective. Molec. Cell. Diff. 2, 1-21 (1994).
26. Counter, C.M., Botelho, F.M., Wang, P., Harely, C.B., & Bacchetti, S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus transformed human B lymphocytes. J. Virol 68, 3410-3414 (1994).
27. Counter, C.M., Hirte, H. W., Bacchetti, S. & Harley, C.B. Telomerase activity in human ovarian carcinoma. Proc. natn. Acad. Sci. U.S.A. 91, 2900-2904 (1994).
28. Shay, J.W., Tomlinson, G., Piatyszek, M.A., & Gollahon, L. Spontaneous in vitro immortalization of breast epithelial cells from a Li-Fraumeni patient. Molec. Cell Biol 15, 425-432 (1995).
29. Young, J.L., Ries, L.G., Silverberg, E., Horm, J.W. & Miller, R.W. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 56, 598-602 (1986).
30. Sawada, T. et al. Long-term effects of mass screening for neuroblastoma in infancy. Am. J. Pediatr. Hematol. Oncol 13, 3-7 (1991).
31. Evans, A.E., Gerson, J. & Schnaufer, L. Spontaneous regression of neuroblastoma. Natn. Cancer Inst Monogr. 44, 49-54 (1976).
32. Woods, W.G., Lemieux, B. & Tuchman, M. Neuroblastoma represents distinct clinical-biologic entities: A review and perspective from the Quebec neuroblastoma screening project. Pediatrics 89, 114-118 (1992).
33. Brodeur, G.M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol 11, 1466-1477 (1993).
34. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E. & Bishop, J.M. Amplification of N-mγc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-1124 (1984).
35. D'Angio, G.J., Evans, A.E. & Koop, C.E. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet i, 1046-1049 (1971).
36. Evans, A.E., Baum, E. & Chard, R. Do infants with stage IV-S neuroblastoma need treatment? Arch. Dis. Child 56, 271-274 (1981).
37. Kretschmar, C.S. et al. Improved prognosis for infants with stage IV neuroblastoma. J. Clin. Oncol 2, 799-803 (1984).
38. Finklestein, J.Z. et al. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med. Pediatr. Oncol 6, 179-188 (1979).
39. Evans, A.E., D'Angio, G.J. & Randolf, J. A proposed staging for children with neuroblastoma. Cancer 27, 374-378 (1971).
40. Seeger, R.C. et al. Association of multiple copies of the N-mγc oncogene with rapid progression of neuroblastomas. New Engl. J. Med. 313, 1111-1116 (1985).
41. Hayashi, Y. et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 63, 126-132 (1989).
42. Fong, C. et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-mγc amplification. Proc. natn. Acad. Sci. U.SA. 86, 3753-3757 (1989).
43. Hellstrom, I., Hellstrom, K.E., Pierce, G.E., & Bill, A.H. Demonstration of cell- bound and humoral immunity against neuroblastoma cells. Proc. natn. Acad. Sci. USA. 60, 1231-1238 (1968).
44. Rangecroft, L., Lauder, I., & Wagget, J. Spontaneous maturation of stage IV-S neuroblastoma. Arch Dis. Child 52, 815-817 (1978).
45. Hiyama, E., Hiyama, K., Yokoyama, T., Ichikawa, T. & Matsuura, Y. Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics. Jap. J. Cancer Res. 83, 159-164 (1992).
46. Shimada, H. et al. Histopathologic prognostic factors in neuroblastic tumours. J. natn. Cancer Inst 73, 405-416 (1984).
47. Hiyama, E. et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int. J. Oncol 6, 13-16 (1995).
48. Turkel, S.B. & Itabashi, H.H. The natural history of neuroblastic cells in the fetal adrenal gland. Am. J. Path. 76, 225-244 (1974).
49. Ikeda, Y., Lister, J., Bouton, J.M. & Buyukpamukcu, M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J. Pediatr. Surg. 16, 636-644 (1981).
50. Schwartz, H.S., Dhair, G.A. & Butler, M.G. Telomere reduction in giant cell tumour of bone and with age. Cancer Genet. Cytogenet. 71, 132-138 (1993).
51. Mehle, C., Ljungberg, B. & Roos, G. Telomere shortening in renal cell carcinoma. Cancer Res. 54, 236-241 (1994).
52. Nürnberg, P., Thiel, G., Weber, F. & Epplen, J.T. Changes of telomere lengths in human intracranial tumours. Human Genet 91, 190-192 (1993).
53. Schmitt, H., Blin, N. Zankl, H. & Scherthan, H. Telomere length variation in normal and malignant human tissue. Genes Chrom. & Cancer 11, 171-177 (1994).
54. Prichard, J. & Hickman, J.A., Why does stage 4s neuroblastoma regress spontaneously? Lancet 344, 869-870 (1994).
55. James, D.H., Hutsu, O., Wrenn, E.L., & Pinkel, D. Combination chemotherapy of childhood neuroblastoma. JAMA 194, 123-126 (1965).
56. Sawaguchi, S. et al. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Study Group of Japan. Cancer 66, 1879-1887 (1990).